Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by smartin5493on Jun 10, 2007 9:51am

367 Views

Post# 12919813

RE: Target Price

The 3 mac`s have been accumalating shr`s for several months now.They must have good reason and insight.With the sudden shr price increase up to 1.93 (however did not hold)may be indication that someone knows something and a major NR is soon coming.Maybe a deal with a big pharma company has been inked which would push this stock much higher.$20 seems like a reach but hell I am in for the ride.I just hope the bashers don`t come to this board once the stock takes off.

Bullboard Posts

First Helium advances winter drilling program with Leduc Anomaly test well